Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 14, 2024 08:00 ET
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of...
May 14, 2024 08:00 ET
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each...
May 14, 2024 08:00 ET
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a leading global investment firm, of up to $475 million, with approximately $375 million funded...
May 14, 2024 08:00 ET
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that an independent...
May 14, 2024 08:00 ET
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the...
May 14, 2024 08:00 ET
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced it...
May 14, 2024 08:00 ET
BranchOut Food Secures Large Scale Production Facility in Peru Capable of $40M in Production Capacity; Estimated 40-50% Gross Margins
BranchOut Food Inc. (NASDAQ: BOF), a pioneering food technology company and producer of dehydrated fruit and vegetable-based products, today announced that it has signed a long term lease for a 50,000 square foot production facility in Peru. Under...
May 14, 2024 08:00 ET
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first...
May 14, 2024 08:00 ET
Clene to Present at Upcoming May Conferences
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to...
May 14, 2024 08:00 ET
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a...
May 14, 2024 08:00 ET
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended March 31, 2024 and provided a company update. “The progress across our portfolio in the...
May 14, 2024 08:00 ET
Design 1st and Swabbot Elevate Industrial Cleaning with Collaborative Robot Solution Engineered for Precision, Safety, and Efficiency
Design 1st, one of the most prolific full-service product design-engineering firms across North America, in partnership with Swabbot, announced today the launch of the collaborative robot (cobot) aimed at redefining industrial cleaning. Developed...
May 14, 2024 08:00 ET
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic...
May 14, 2024 08:00 ET
Freshworks to Participate in Upcoming Investor Conferences
Freshworks Inc., (NASDAQ: FRSH) today announced participation in the following events: J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference: Dennis Woodside, Chief Executive Officer, is scheduled to participate in a...
May 14, 2024 08:00 ET
ManTech Wins $110 Million Air Force Contract for Human Capital Transformation and AI
ManTech, a leading provider of artificial intelligence (AI) and mission-focused technology solutions, has won a $110 million contract with the U.S. Air Force. Under this three-year prime contract ManTech will help transform data and enterprise...
May 14, 2024 08:00 ET
Mondelēz International Showcases Sweet Collaborations & Omnichannel Expertise at Sweets & Snacks Expo
Mondelēz International, Inc. (Nasdaq: MDLZ) will showcase key innovations and tasty collaborations to accelerate brand loyalty and growth at the 2024 Sweets and Snacks Expo in Indianapolis, IN, on May 15. Among many highlights, the company will...
May 14, 2024 08:00 ET
Northann Corp. Announces Strategic Partnership with Adornus Cabinetry
Northann Corp. (NYSE American: NCL), a leader 3D printing home improvement solutions, today announced a strategic partnership with Adornus Cabinetry, a South Carolina-based manufacturer of luxury cabinetry. The partnership will focus on combining...
May 14, 2024 08:00 ET
One in Three Consumers Victimized by Fraud on Gig Economy Platforms
More than one-third of American consumers have been victimized by fraud while using gig economy platforms, like delivery and ride-sharing apps, according to a new report from TransUnion (NYSE: TRU). This represents a 21% increase from its last...
May 14, 2024 08:00 ET
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has...
May 14, 2024 08:00 ET
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the first quarter...